Joshi J Alumkal

List of Publications by Year
in descending order

67 papers	4,655 citations	236925 25 h-index	161849 54 g-index
74 all docs	74 docs citations	74 times ranked	6561 citing authors

#	Article	IF	Citations
1	Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1â€"2 study. Lancet, The, 2010, 375, 1437-1446.	13.7	972
2	Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. Journal of Clinical Oncology, 2018, 36, 2492-2503.	1.6	477
3	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell, 2018, 174, 758-769.e9.	28.9	459
4	Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget, 2016, 7, 52810-52817.	1.8	305
5	Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. Journal of the National Cancer Institute, 2017, 109, .	6.3	288
6	The DNA methylation landscape of advanced prostate cancer. Nature Genetics, 2020, 52, 778-789.	21.4	198
7	A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer. Investigational New Drugs, 2015, 33, 480-489.	2.6	170
8	LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E4179-E4188.	7.1	160
9	Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 16663-16668.	7.1	155
10	Identifying phenotype-associated subpopulations by integrating bulk and single-cell sequencing data. Nature Biotechnology, 2022, 40, 527-538.	17.5	128
11	Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation. PLoS ONE, 2013, 8, e63563.	2.5	104
12	Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. European Urology, 2019, 76, 562-571.	1.9	104
13	Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 12315-12323.	7.1	87
14	A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer. Clinical Cancer Research, 2020, 26, 5338-5347.	7.0	76
15	MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 531-538.	3.9	66
16	Epigenetic regulation of androgen receptor signaling in prostate cancer. Epigenetics, 2010, 5, 100-104.	2.7	63
17	Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. Molecular Cancer Research, 2019, 17, 1235-1240.	3.4	51
18	Effect of DNA Methylation on Identification of Aggressive Prostate Cancer. Urology, 2008, 72, 1234-1239.	1.0	46

#	Article	IF	Citations
19	Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2019, 25, 52-63.	7.0	44
20	Epigenomic profiling of prostate cancer identifies differentially methylated genes in TMPRSS2:ERG fusion-positive versus fusion-negative tumors. Clinical Epigenetics, 2015, 7, 128.	4.1	35
21	Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate Cancer. European Urology, 2021, 80, 71-81.	1.9	35
22	Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease. Scientific Reports, 2020, 10, 21750.	3.3	34
23	BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program. Clinical Cancer Research, 2021, 27, 4923-4936.	7.0	33
24	Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer. Scientific Reports, 2019, 9, 3823.	3.3	32
25	CTâ€"Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield. Journal of Vascular and Interventional Radiology, 2017, 28, 1073-1081.e1.	0.5	30
26	The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches. Endocrine-Related Cancer, 2021, 28, T51-T66.	3.1	28
27	Multi-Omics Analyses Detail Metabolic Reprogramming in Lipids, Carnitines, and Use of Glycolytic Intermediates between Prostate Small Cell Neuroendocrine Carcinoma and Prostate Adenocarcinoma. Metabolites, 2019, 9, 82.	2.9	27
28	Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial. Clinical Genitourinary Cancer, 2017, 15, 610-617.e3.	1.9	25
29	Understanding Drug Sensitivity and Tackling Resistance in Cancer. Cancer Research, 2022, 82, 1448-1460.	0.9	24
30	BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer. Oncogene, 2019, 38, 5658-5669.	5.9	23
31	Reversal of the Warburg phenomenon in chemoprevention of prostate cancer by sulforaphane. Carcinogenesis, 2019, 40, 1545-1556.	2.8	21
32	Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer. JAMA Oncology, 2021, 7, 1644.	7.1	21
33	Emerging Therapies in Castrate-Resistant Prostate Cancer. Current Urology Reports, 2010, 11, 152-158.	2.2	20
34	Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4. Neoplasia, 2020, 22, 253-262.	5.3	19
35	De novo neuroendocrine transdifferentiation in primary prostate cancerâ€"a phenotype associated with advanced clinico-pathologic features and aggressive outcome. Medical Oncology, 2021, 38, 26.	2.5	18
36	RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer. Cancer Research, 2021, 81, 4736-4750.	0.9	18

#	Article	IF	Citations
37	A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancer. Epigenetics, 2011, 6, 1248-1256.	2.7	16
38	Diagnostic and Prognostic Utility of a DNA Hypermethylated Gene Signature in Prostate Cancer. PLoS ONE, 2014, 9, e91666.	2.5	13
39	Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. Oncotarget, 2016, 7, 40690-40703.	1.8	12
40	Ipilimumab (IPI) in metastatic castrate-resistant prostate cancer (mCRPC): Results from an open-label, multicenter phase I/II study.. Journal of Clinical Oncology, 2012, 30, 25-25.	1.6	11
41	Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2020, 26, 4616-4624.	7.0	10
42	Autoantibody Landscape in Patients with Advanced Prostate Cancer. Clinical Cancer Research, 2020, 26, 6204-6214.	7.0	10
43	Modeling Androgen Deprivation Therapyâ€"Induced Prostate Cancer Dormancy and Its Clinical Implications. Molecular Cancer Research, 2022, 20, 782-793.	3.4	10
44	Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF. Clinical Genitourinary Cancer, 2015, 13, e191-e198.	1.9	9
45	The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity. Frontiers in Endocrinology, 0, 13, .	3.5	9
46	Distinct Epigenetic Mechanisms Distinguish<i>TMPRSS2â€"ERG</i> Fusion-Positive and -Negative Prostate Cancers. Cancer Discovery, 2012, 2, 979-981.	9.4	8
47	Immunohistochemical expression of ERG in the molecular epidemiology of fatal prostate cancer study. Prostate, 2013, 73, 1371-1377.	2.3	7
48	Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 316-323.	3.9	6
49	Multigene Profiling of Circulating Tumor Cells (CTCs) for Prognostic Assessment in Treatment-NaÃ¯ve Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). International Journal of Molecular Sciences, 2022, 23, 4.	4.1	6
50	Abstract CT095: A Phase Ib/IIa study of the BET bromodomain inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). Cancer Research, 2019, 79, CT095-CT095.	0.9	5
51	Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 931.e9-931.e16.	1.6	4
52	Double-Negative Prostate Cancer Masquerading as a Squamous Cancer of Unknown Primary: A Clinicopathologic and Genomic Sequencing-Based Case Study. JCO Precision Oncology, 2020, 4, 1386-1392.	3.0	4
53	Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity. Journal of Biological Chemistry, 2022, 298, 101556.	3.4	4
54	A CHIP in the Armor of Cell-Free DNAâ€"Based Predictive Biomarkers for Prostate Cancer. JAMA Oncology, 2021, 7, 111.	7.1	2

#	Article	IF	Citations
55	Reply to A. Dalla Volta et al. Journal of Clinical Oncology, 2019, 37, 351-352.	1.6	0
56	Sinking Prostate Cancer from Under the Sea. Science Translational Medicine, 2010, 2, .	12.4	0
57	<i>TMPRSS2-ERG</i> , a Mover and a Shaker. Science Translational Medicine, 2010, 2, .	12.4	0
58	Precious Metals. Science Translational Medicine, 2010, 2, .	12.4	0
59	Abrogating Angiogenesis Just Got EZier. Science Translational Medicine, 2010, 2, .	12.4	0
60	Reducing the UnSIRTainty of Alzheimerâ€™s Disease. Science Translational Medicine, 2010, 2, .	12.4	0
61	A New â€œFixâ€•for Cancer. Science Translational Medicine, 2010, 2, .	12.4	0
62	An Expanded Tumor Playing Field. Science Translational Medicine, 2010, 2, .	12.4	0
63	Turning Off the Cancer Switch. Science Translational Medicine, 2010, 2, .	12.4	0
64	Drugging Bugs to Make Chemotherapy Safer. Science Translational Medicine, 2010, 2, .	12.4	0
65	Thinking Outside the Box in Prostate Cancer. Science Translational Medicine, 2010, 2, .	12.4	0
66	JAK and Jumonji: Deadly Playmates. Science Translational Medicine, 2011, 3, .	12.4	0
67	An Epigenetic Road to Genome Instability. Science Translational Medicine, 2011, 3, .	12.4	0